VD
Dutoit Vallotton, Valérie
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Targeting HIF-2α in glioblastoma reshapes the immune infiltrate and enhances response to immune checkpoint blockade | Cellular and molecular life sciences |  | 2025 | 152 | 49 | ||
| Magnetic bead-sensitized optoporation coupled with antibodies-based activation for mRNA CAR-T cell manufacturing | Molecular therapy. Methods & clinical development | | 2025 | 48 | 76 | ||
| PTPRZ1-targeting RNA CAR T cells exert antigen-specific and bystander antitumor activity in glioblastoma | Cancer immunology research | | 2024 | 289 | 247 | ||
| A novel mitochondrial pyruvate carrier inhibitor drives stem cell-like memory CAR T cell generation and enhances antitumor efficacy | Molecular therapy. Oncology | | 2024 | 133 | 106 | ||
| Radio-chemotherapy of glioblastoma cells promotes phagocytosis by macrophages in vitro | Radiotherapy and oncology | | 2024 | 106 | 23 | ||
| Hypoxic glioblastoma-cell-derived extracellular vesicles impair cGAS-STING activity in macrophages | Cell communication and signaling | | 2024 | 129 | 52 | ||
| Neoantigen-specific T-cell response after donor lymphocyte infusion associates with favorable outcome in a patient with i(12p) germ cell tumor, acute leukemia and sarcoma of the same clonal origin | Haematologica | | 2024 | 100 | 74 | ||
| Promises and challenges of predictive blood biomarkers for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy | Cells | | 2023 | 111 | 127 | ||
| PTPRZ1-targeting RNA CAR-T cells exert antigen-specific and bystander antitumor activity in glioblastoma | | 2023 | 232 | 477 | |||
| Identification of a miRNA multi-targeting therapeutic strategy in glioblastoma | Cell death and disease | | 2023 | 322 | 85 | ||
| c-Met+ Cytotoxic T Lymphocytes Exhibit Enhanced Cytotoxicity in Mice and Humans In Vitro Tumor Models | Biomedicines | | 2023 | 52 | 48 | ||
| Study protocol of a phase II study to evaluate safety and efficacy of neo-adjuvant pembrolizumab and radiotherapy in localized rectal cancer | BMC cancer | | 2022 | 252 | 128 | ||
| Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer | iScience | | 2022 | 236 | 148 | ||
| Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma | Frontiers in Immunology | | 2021 | 459 | 316 | ||
| Emerging Trends for Radio-Immunotherapy in Rectal Cancer | Cancers | | 2021 | 54 | 85 | ||
| Clonal Evolution of a High-Grade Pediatric Glioma With Distant Metastatic Spread | Neurology Genetics | | 2021 | 331 | 81 | ||
| Metataxonomic and Metabolic Impact of Fecal Microbiota Transplantation From Patients With Pancreatic Cancer Into Germ-Free Mice: A Pilot Study | Frontiers in cellular and infection microbiology | | 2021 | 339 | 122 | ||
| Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells | Communications Biology | | 2021 | 341 | 195 | ||
| Oncolytic Viruses as a Platform for the Treatment of Malignant Brain Tumors | International Journal of Molecular Sciences | | 2020 | 291 | 262 | ||
| An experimentally defined hypoxia gene signature in glioblastoma and its modulation by metformin | Biology (Basel)[2079-7737] | | 2020 | 482 | 286 | ||
| Inflammation and lymphocyte infiltration are associated with shorter survival in patients with high-grade glioma | OncoImmunology | | 2020 | 456 | 276 | ||
| Impact of Radiochemotherapy on Immune Cell Subtypes in High-Grade Glioma Patients | Frontiers in Oncology | | 2020 | 351 | 126 | ||
| Stratégies de vaccination thérapeutique dans le glioblastome | Medecine Sciences | | 2020 | 212 | 358 | ||
| Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review | Journal for immunotherapy of cancer | | 2020 | 199 | 233 | ||
| Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma | Molecular and Cellular Proteomics |  | 2019 | 432 | 2 | ||
| Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients | Neuro-Oncology | | 2019 | 840 | 502 | ||
| Current strategies for vaccination in glioblastoma | Current Opinion in Oncology | | 2019 | 396 | 5 | ||
| Peptides as cancer vaccines | Current Opinion in Pharmacology | | 2019 | 423 | 4 | ||
| Actively personalized vaccination trial for newly diagnosed glioblastoma | Nature | | 2019 | 561 | 12 | ||
| Exploratory study of the effect of IMA950/poly-ICLC vaccination on response to bevacizumab in relapsing high-grade glioma patients | Cancers | | 2019 | 366 | 181 | ||
| Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma | Molecular and Cellular Proteomics | | 2018 | 438 | 2 | ||
| Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma | OncoImmunology | | 2018 | 663 | 333 | ||
| First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies | OncoImmunology | | 2017 | 650 | 9 | ||
| Immunothérapie des gliomes : illusion ou espoir ? | Bulletin du cancer | 2017 | 421 | 0 | |||
| ER-mitochondria contacts control surface glycan expression and sensitivity to killer lymphocytes in glioma stem-like cells | EMBO Journal | | 2017 | 620 | 10 | ||
| Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma | Cancer Cell | | 2017 | 514 | 5 | ||
| Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites? | Frontiers in Oncology | | 2016 | 530 | 417 | ||
| Human tissue engineering allows the identification of active miRNA regulators of glioblastoma aggressiveness | Biomaterials | | 2016 | 560 | 5 | ||
| Ipilimumab-related hypophysitis may precede severe CNS immune attack | Annals of Oncology | | 2016 | 457 | 0 | ||
| Identification of glioma-associated antigens for brain tumor immunotherapy | | 2015 | 670 | 534 | |||
| Immunotherapy of Brain Tumors | Progress in tumor research | 2015 | 584 | 0 | |||
| Immunotherapy for glioma: from illusion to realistic prospects? | American Society of Clinical Oncology educational book | | 2014 | 1,270 | 616 | ||
| Comprehensive metagenomic analysis of glioblastoma reveals absence of known virus despite antiviral-like type I interferon gene response | International journal of cancer | | 2014 | 747 | 417 | ||
| Extrachromosomal driver mutations in glioblastoma and low-grade glioma | Nature communications | | 2014 | 766 | 228 | ||
| Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08) | European urology | | 2013 | 594 | 0 | ||
| The relationship between brain tumor cell invasion of engineered neural tissues and in vivo features of glioblastoma | Biomaterials | | 2013 | 729 | 6 | ||
| Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy | Brain | | 2012 | 705 | 1,396 |
